Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies
Open accessAbstract
BACKGROUND: Immune checkpoint inhibitors (ICPIs) are increasingly being used in the treatment of a variety of malignancies. The original studies that demonstrated the efficacy of ICPIs excluded patients actively being treated for autoimmune conditions, and there is only limited evidence that these treatments are safe and effective in this population of patients. CASE PRESENTATION: We present a case of a man with Crohn's disease actively requiring immunosuppressive therapy who subsequently received pembrolizumab for metastatic melanoma. He had no further progression of metastatic disease and had resolution of his pulmonary nodule while he experienced no Crohn's disease flares or immune related adverse events. We surveyed the existing literature for studies examining the use of ICPIs in patients with autoimmune disorders and reviewed the unique mechanism of action of the α4β7 inhibitor, vedolizumab. CONCLUSION: Patients with autoimmune conditions should be considered candidates for immune checkpoint inhibition even in the setting of active immunosuppressive therapy. The mechanism of action of immunosuppressive therapy should be considered with the most targeted form of treatment being used when possible. Further prospective studies investigating immunotherapy in patients with autoimmune conditions are warranted.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Vedolizumab can be administered concomitantly with immune-checkpoint inhibitors in active IBD likely without either IBD exacerbation or compromising ICI efficiency.
“Furthermore, VDZ could be administered concomitantly with ICIs in active IBD likely without either IBD exacerbation or compromising ICI efficiency.18”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · see citing works
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · see citing works
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849 · see citing works
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P. J., Hanauer, S. B., Colombel, J., Sands, B. E., Lukáš, M., Fedorak, R. N., Lee, S., Bressler, B. L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,716 · see citing works
Using immunotherapy to boost the abscopal effect
Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., & Formenti, S. C. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.6 · Cited by 1,260 · see citing works
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,090 · see citing works
Menzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw443 · Cited by 817 · see citing works
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642 · see citing works
Luke, J. J., Lemons, J. M., Karrison, T. G., Pitroda, S. P., Melotek, J. M., Zha, Y., Al-Hallaq, H. A., Arina, A., Khodarev, N. N., Janisch, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.2229 · Cited by 588 · see citing works
Self-citationWeber, J. S., Thompson, J. A., Hamid, O., Minor, D. R., Amin, A., Ron, I. G., Ridolfi, R., Assi, H. I., Maraveyas, A., Berman, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1024 · Cited by 566 · see citing works
Abdel-Wahab, N., Shah, M., Lopez-Olivo, M. A., & Suarez-Almazor, M. E. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2073 · Cited by 487 · see citing works
Leonardi, G. C., Gainor, J. F., Altan, M., Kravets, S., Dahlberg, S. E., Gedmintas, L., Azimi, R., Rizvi, H., Riess, J. W., Hellmann, M. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0305 · Cited by 341 · see citing works
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., & Marsal, J. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1962-6 · Cited by 234 · see citing works
Integrin signalling and function in immune cells
Zhang, Y., & Wang, H. (2012) · Immunology · doi:10.1111/j.1365-2567.2011.03549.x · Cited by 207 · see citing works
Roles of the immune system in skin cancer
Rangwala, S., & Tsai, K. Y. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10507.x · Cited by 188 · see citing works
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
Collins, M., Michot, J., Danlos, F. X., Mussini, C., Soularue, É., Mateus, C., Loirat, D., Buisson, A., Rosa, I., Lambotte, O., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx403 · Cited by 153 · see citing works
Abdel‐Wahab, N., Shah, M., Lopez-Olivo, M. A., & Suarez-Almazor, M. E. (2018) · Annals of Internal Medicine · doi:10.7326/l18-0209 · Cited by 63 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordão, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,672 · see citing works
Nooraei, S., Bahrulolum, H., Hoseini, Z. S., Katalani, C., Hajizade, A., Easton, A. J., & Ahmadian, G. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00806-7 · Cited by 879 · see citing works
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750 · see citing works
Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity
Efimova, I., Catanzaro, E., der Meeren, L. V., Turubanova, V. D., Hammad, H., Mishchenko, T. A., Vedunova, M. V., Fimognari, C., Bachert, C., Coppieters, F., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001369 · Cited by 537 · see citing works
Petrelli, F., Cortellini, A., Indini, A., Tomasello, G., Ghidini, M., Nigro, O., Salati, M., Dottorini, L., Iaculli, A., Varricchio, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.3520 · Cited by 530 · see citing works
CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?
Hoyt-Miggelbrink, A. M., Jackson, J. D., Lorrey, S., Srinivasan, E. S., Polania, J. W., Wilkinson, D. S., & Fecci, P. E. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0206 · Cited by 239 · see citing works
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222 · see citing works
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
Abu‐Sbeih, H., Faleck, D. M., Ricciuti, B., Mendelsohn, R. B., Naqash, A. R., Cohen, J. V., Sellers, M. C., Balaji, A., Ben‐Betzalel, G., Ibraheim, H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01674 · Cited by 206 · see citing works
Seo, K., Yoo, J. H., Kim, J., Min, S. J., Heo, D. N., Kwon, I. K., & Moon, H. (2023) · Nanoscale · doi:10.1039/d2nr07018a · Cited by 149 · see citing works
Kristensen, N. P., Heeke, C., Tvingsholm, S. A., Borch, A., Draghi, A., Crowther, M. D., Carri, I., Munk, K. K., Holm, J. S., Bjerregaard, A.-M., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci150535 · Cited by 140 · see citing works
A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy
Sanmamed, M. F., Nie, X., Desai, S., Villarroel‐Espíndola, F., Badri, T., Zhao, D., Kim, A. W., Ji, L., Zhang, T., Quinlan, E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0962 · Cited by 140 · see citing works
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C. G., & Varricchi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804597 · Cited by 130 · see citing works
The current knowledge concerning solid cancer and therapy
Najafi, M., Majidpoor, J., Toolee, H., & Mortezaee, K. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22900 · Cited by 131 · see citing works
Tong, P., Zhu, L. Z., Zang, Y., Li, J. X., He, X., & James, T. D. (2021) · Chemical Communications · doi:10.1039/d1cc05157a · Cited by 126 · see citing works
A variational algorithm to detect the clonal copy number substructure of tumors from scRNA-seq data
Falco, A. D., Caruso, F. P., Su, X., Iavarone, A., & Ceccarelli, M. (2023) · Nature Communications · doi:10.1038/s41467-023-36790-9 · Cited by 125 · see citing works
Jing, Y., Chen, X., Li, K., Liu, Y., Zhang, Z., Chen, Y., Liu, Y., Wang, Y., Lin, S. H., Diao, L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003779 · Cited by 117 · see citing works
Diet, lipids, and antitumor immunity
Prendeville, H., & Lynch, L. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00781-x · Cited by 122 · see citing works
Checkpoint Inhibitor–Induced Colitis
Bellaguarda, E., & Hanauer, S. B. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000497 · Cited by 106 · see citing works
Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
Young, A., Quach, H. T., Song, H., Davis, E. J., Moslehi, J. J., Ye, F., Williams, G. R., & Johnson, D. B. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000821 · Cited by 105 · see citing works
Kristensen, N. P., Heeke, C., Tvingsholm, S. A., Borch, A., Draghi, A., Crowther, M. D., Carri, I., Munk, K. K., Holm, J. S., Bjerregaard, A.-M., et al. (2021) · UCL Discovery (University College London) · Cited by 105 · see citing works
Effects of immune‐related adverse events ( irAEs ) and their treatment on antitumor immune responses
Blum, S. M., Rouhani, S. J., & Sullivan, R. J. (2023) · Immunological Reviews · doi:10.1111/imr.13262 · Cited by 103 · see citing works
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
Klemen, N. D., Wang, M., Rubinstein, J. C., Olino, K. L., Clune, J. E., Ariyan, S., Cha, C. H., Weiss, S. A., Kluger, H. M., & Sznol, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000341 · Cited by 93 · see citing works
MacGregor, H. L., Sayad, A., Elia, A., Wang, B. X., Katz, S. R., Shaw, P. A., Clarke, B. A., Crome, S. Q., Robert-Tissot, C., Bernardini, M. Q., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0816-5 · Cited by 78 · see citing works
Proteogenomics Uncovers a Vast Repertoire of Shared Tumor-Specific Antigens in Ovarian Cancer
Zhao, Q., Laverdure, J., Lanoix, J., Durette, C., Côté, C., Bonneil, É., Laumont, C. M., Gendron, P., Vincent, K., Courcelles, M., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0541 · Cited by 75 · see citing works
Alrasheed, N., Lee, L. S. H., Ghorani, E., Henry, J. Y., Conde, L., Chin, M., Galas‐Filipowicz, D., Furness, A. J. S., Chavda, S. J., Richards, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1714 · Cited by 74 · see citing works
Risk factors for immune-related adverse events: what have we learned and what lies ahead?
Liu, X., Shi, Y., Zhang, D., Zhou, Q., Liu, J., Chen, M., Xu, Y., Zhao, J., Zhong, W., & Wang, M. (2021) · Biomarker Research · doi:10.1186/s40364-021-00314-8 · Cited by 74 · see citing works
Adverse events induced by immune checkpoint inhibitors
Perdigoto, A. L., Kluger, H. M., & Herold, K. C. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.002 · Cited by 77 · see citing works
Targeting extracellular matrix stiffness for cancer therapy
Feng, X., Cao, F., Wu, X., Xie, W., Wang, P., & Jiang, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1467602 · Cited by 73 · see citing works
Ishihara, M., Kitano, S., Kageyama, S., Miyahara, Y., Yamamoto, N., Kato, H., Mishima, H., Hattori, H., Funakoshi, T., Kojima, T., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003811 · Cited by 69 · see citing works
Nanobiotechnology-assisted therapies to manage brain cancer in personalized manner
Nehra, M., Uthappa, U. T., Kumar, V., Kumar, R., Dixit, C. K., Dilbaghi, N., Mishra, Y. K., Kumar, S., & Kaushik, A. K. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.027 · Cited by 68 · see citing works
Cooperative phagocytosis of solid tumours by macrophages triggers durable anti-tumour responses
Dooling, L. J., Andrechak, J. C., Hayes, B. H., Kadu, S., Zhang, W., Pan, R., Vashisth, M., Irianto, J., Alvey, C. M., Ma, L., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01031-3 · Cited by 65 · see citing works
Khalique, H., Baugh, R. T., Dyer, A., Scott, E. M., Frost, S., Larkin, S. J., Lei-Rossmann, J., & Seymour, L. W. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001292 · Cited by 62 · see citing works
Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy
Shin, D. H., Nguyen, T. T., Özpolat, B., Lang, F. F., Alonso, M. M., Gomez‐Manzano, C., & Fueyo-Margareto, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002086 · Cited by 57 · see citing works
Lechner, M. G., Patel, A. Y., Hugo, W., Angell, T. E., Cheng, M. I., Pioso, M. S., Hoang, A. T., Yakobian, N., McCarthy, E. C., Chen, H.-C., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2200244 · Cited by 56 · see citing works
Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer
Hagiwara, Y., Shiroiwa, T., Taira, N., Kawahara, T., Konomura, K., Noto, S., Fukuda, T., & Shimozuma, K. (2020) · Health and Quality of Life Outcomes · doi:10.1186/s12955-020-01611-w · Cited by 55 · see citing works
EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
Zhang, Z., Wu, H., Lin, W., Wang, Z., Yang, L.-P., Zeng, Z.-L., & Luo, H. (2021) · BMC Medicine · doi:10.1186/s12916-020-01899-x · Cited by 55 · see citing works
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma
Wang, Y., Deng, J., Wang, L., Zhou, T., Yang, J., Tian, Z., Yang, J., Chen, H., Tang, X., Zhao, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000406 · Cited by 54 · see citing works
Lomphithak, T., Akara-amornthum, P., Murakami, K., Hashimoto, M., Usubuchi, H., Iwabuchi, E., Unno, M., Cai, Z., Sasano, H., & Jitkaew, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-89977-9 · Cited by 53 · see citing works
Exploring TGF-β Signaling in Cancer Progression: Prospects and Therapeutic Strategies
Sheikh, K., Amjad, M., Irfan, M., Anjum, S., Majeed, T., Riaz, M. U., Jassim, A. Y., Sharif, E., & Ibrahim, W. N. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s493643 · Cited by 57 · see citing works
The dark side of immunotherapy
Okwundu, N., Grossman, D., Hu‐Lieskovan, S., Grossmann, K. F., & Swami, U. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4750 · Cited by 47 · see citing works
Genetically engineered bacteria: a new frontier in targeted drug delivery
Fooladi, S., Rabiee, N., & Iravani, S. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb01805a · Cited by 49 · see citing works
Heras‐Murillo, I., Mañanes, D., Munné, P., Núñez, V., Herrera, J., Català-Montoro, M., Álvarez, M., del Pozo, M. Á., Melero, I., Wculek, S. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58289-1 · Cited by 48 · see citing works
Grover, S., Ruan, A. B., Srivoleti, P. D., Giobbie‐Hurder, A., Braschi‐Amirfarzan, M., Srivastava, A., Buchbinder, E. I., Ott, P. A., Kehl, K. L., Awad, M. M., et al. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00672 · Cited by 48 · see citing works
Coureau, M., Meert, A., Berghmans, T., & Grigoriu, B. D. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00137 · Cited by 46 · see citing works
Liu, X., Lou, K., Zhang, Y. ‐. P., Li, C., Wei, S., & Feng, S. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s463145 · Cited by 46 · see citing works
Melssen, M. M., Fisher, C. T., Slingluff, C. L., & Melief, C. J. M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004709 · Cited by 43 · see citing works
Ren, K., Ma, J., Zhou, B., Lin, X., Hou, M., Zhang, L., Yuan, L., & Ma, J. (2020) · Materials Express · doi:10.1166/mex.2020.1736 · Cited by 41 · see citing works
Yuan, H., Ma, J., Huang, W., Gong, P., Shi, F., Xu, X., Fu, C., Wang, X., Wong, Y. K., Long, Y., et al. (2023) · JACS Au · doi:10.1021/jacsau.3c00156 · Cited by 41 · see citing works
Modulation of the Host Cell Transcriptome and Epigenome by Fusobacterium nucleatum
Despins, C. A., Brown, S. D., Robinson, A. V., Mungall, A. J. J., Allen‐Vercoe, E., & Holt, R. A. (2021) · mBio · doi:10.1128/mbio.02062-21 · Cited by 40 · see citing works
Wang, X., Muzaffar, J., Kirtane, K., Song, F., Johnson, M. J., Schell, M. J., Li, J., Yoder, S., Conejo-Garcia, J. R., Guevara-Patino, J. A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004512 · Cited by 40 · see citing works
Tateo, V., Manuzzi, L., Giglio, A. D., Parisi, C., Lamberti, G., Campana, D., & Pantaleo, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239056 · Cited by 39 · see citing works
Tay, A. H. M., Prieto‐Díaz, R., Neo, S., Tong, L., Chen, X., Carannante, V., Önfelt, B., Hartman, J., Haglund, F., Majellaro, M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004592 · Cited by 37 · see citing works
Riaz, S., Ali, S., Summer, M., Akhtar, U., Noor, S., Haqqi, R., Farooq, M. A., & Sardar, I. (2025) · Annals of Biomedical Engineering · doi:10.1007/s10439-025-03712-3 · Cited by 37 · see citing works
Computational frameworks transform antagonism to synergy in optimizing combination therapies
Chen, J., Lin, A., Jiang, A., Qi, C., Liu, Z., Cheng, Q., Yuan, S., & Luo, P. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01435-2 · Cited by 37 · see citing works
Immunotherapy Use in Patients With Lung Cancer and Comorbidities
von Itzstein, M. S., Gonugunta, A. S., Mayo, H., Minna, J. D., & Gerber, D. E. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000484 · Cited by 33 · see citing works
Sharifiaghdam, M., Shaabani, E., Sharifiaghdam, Z., Keersmaecker, H. D., Lucas, B., Lammens, J., Ghanbari, H., Teimoori‐Toolabi, L., Vervaet, C., Beer, T. D., et al. (2021) · Nanoscale · doi:10.1039/d1nr03830c · Cited by 32 · see citing works
PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
Zhang, K., Kong, X., Li, Y., Wang, Z., Zhang, L., & Xuan, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.854967 · Cited by 34 · see citing works
Tumor rejection in Cblb −/− mice depends on IL-9 and Th9 cells
Schanz, O., Cornez, I., Yajnanarayana, S. P., David, F. S., Peer, S., Gruber, T., Krawitz, P. M., Brossart, P., Heine, A., Landsberg, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002889 · Cited by 28 · see citing works
Zhang, S., Gong, C., Ruiz-Martínez, Á., Wang, H., Davis-Marcisak, E. F., Deshpande, A. M., Popel, A. S., & Fertig, E. J. (2021) · ImmunoInformatics · doi:10.1016/j.immuno.2021.100002 · Cited by 29 · see citing works
Prospects of plant-derived exosome-like nanocarriers in oncology and tissue engineering
Rahmati, S., Karimi, H., Alizadeh, M., Khazaei, A. H., Paiva‐Santos, A. C., Rezakhani, L., & Sharifi, E. (2023) · Human Cell · doi:10.1007/s13577-023-00994-4 · Cited by 29 · see citing works
Li, Z., Liu, Y., Zhou, K., Cao, L., Wang, G.-R., Wu, J., Yu, Y., Xiao, Y., Liu, B. Y., Wu, Q., et al. (2025) · Advanced Science · doi:10.1002/advs.202502154 · Cited by 28 · see citing works
Yang, Z., Zhou, L., Si, T., Chen, S., Liu, C., Ng, K. K., Wang, Z., Chen, Z., Qiu, C., Liu, G., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01727-9 · Cited by 28 · see citing works
Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer
Kaufman, B., Abramov, O., Ievko, A., Apple, D., Shlapobersky, M., Allon, I., Greenshpan, Y., Bhattacharya, B., Cohen, O., Charkovsky, T., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg2809 · Cited by 25 · see citing works
Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
Zhang, M., Liu, K., & Wang, M. (2019) · RSC Advances · doi:10.1039/c9ra04590b · Cited by 26 · see citing works
He, X., Zhou, S., Dolan, M., Shi, Y., Wang, J., Quinn, B., Jahagirdar, D., Huang, W., Tsuji, M., Пили, Р., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003101 · Cited by 24 · see citing works
Immunotherapy for Management of Thymic Epithelial Tumors: A Double-Edged Sword
Ballman, M., Zhao, C. N., McAdams, M. J., & Rajan, A. (2022) · Cancers · doi:10.3390/cancers14092060 · Cited by 24 · see citing works
Ribosomal proteins: the missing piece in the inflammation puzzle?
Das, A. S., Basu, A., & Mukhopadhyay, R. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05050-9 · Cited by 23 · see citing works
McLean, L. S., Lim, A., Bressel, M., Lee, J. H., Ladwa, R., Guminski, A., Hughes, B., Bowyer, S. E., Briscoe, K., Harris, S., et al. (2024) · Medical Journal of Australia · doi:10.5694/mja2.52199 · Cited by 23 · see citing works
FAM3 family genes are associated with prognostic value of human cancer: a pan-cancer analysis
Dong, Q.-T., Ma, D.-D., Gong, Q., Lin, Z., Li, Z., Ye, J., Qin, C.-H., Jin, W., Zhang, J., & Zhang, Z. (2023) · Scientific Reports · doi:10.1038/s41598-023-42060-x · Cited by 20 · see citing works
Wu, C., Li, Z., Wu, Q., Lin, S., & Xie, X. (2021) · Immunotherapy · doi:10.2217/imt-2020-0230 · Cited by 20 · see citing works
van Pul, K. M., Vuylsteke, R. J. C. L. M., de Beijer, M. T. A., van de Ven, R., van den Tol, M. P., Stockmann, H. B. A. C., & de Gruijl, T. D. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000761 · Cited by 19 · see citing works
Powles, R. L., Wali, V. B., Li, X., Barlow, W. E., Nahleh, Z. A., Thompson, A. M., Godwin, A. K., Hatzis, C., & Pusztai, L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2405 · Cited by 18 · see citing works
Zhong, Y., Wang, Y., Wang, C.-Y., Cao, K., Wang, X.-L., Xu, X.-Y., Yang, M.-R., Zhang, G.-D., Liu, H.-O., & Lu, J.-Q. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011230 · Cited by 19 · see citing works
Căruntu, A., Scheau, C., Tampa, M. Ş., Georgescu, S. R., Căruntu, C., & Tănase, C. (2021) · Advances in experimental medicine and biology · doi:10.1007/5584_2021_626 · Cited by 18 · see citing works
Carlson, P. M., Patel, R. B., Birstler, J., Rodriquez, M., Sun, C. X., Erbe, A. K., Bates, A. M., Marsh, I. R., Grudzinski, J. J., Hernandez, R., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005463 · Cited by 17 · see citing works
Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review
Silva, V., & Matos, C. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03491-8 · Cited by 15 · see citing works
Management of Cutaneous Angiosarcoma: an Update Review
Bi, S., Zhong, A., Yin, X., Li, J., Cen, Y., & Chen, J. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00933-1 · Cited by 17 · see citing works
STING Protein‐Based In Situ Vaccine Synergizes CD4+ T, CD8+ T, and NK Cells for Tumor Eradication
He, Y., Hong, C., Huang, S., Kaskow, J. A., Covarrubias, G., Pires, I. S., Sacane, J. C., Hammond, P. T., & Belcher, A. M. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300688 · Cited by 15 · see citing works
Jahan, F., Penna, L., Luostarinen, A., Veltman, L., Hongisto, H., Lähteenmäki, K., Müller, S., Ylä‐Herttuala, S., Korhonen, M. O., Vettenranta, K. K., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-76791-2 · Cited by 16 · see citing works
Weingarden, A. R., Rubin, S. J. S., & Gubatan, J. M. B. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i8.772 · Cited by 16 · see citing works
Krejci, I., Heinzmann, J. L., & Lutz, F. (1990) · PubMed · Cited by 16 · see citing works
RETRACTED ARTICLE: Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy
Quazi, S. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07147-0 · Cited by 17 · see citing works
RetractedOzawa, N., Yokobori, T., Osone, K., Katayama, C., Suga, K., Komine, C., Shibasaki, Y., Shiraishi, T., Okada, T., Kato, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92530-3 · Cited by 14 · see citing works
Reyes, A., Mohanty, A. R., Pharaon, R. R., & Massarelli, E. (2022) · Biomedicines · doi:10.3390/biomedicines11010099 · Cited by 18 · see citing works
Belfiore, M. P., Nardone, V., D’Onofrio, I., Pirozzi, M., Sandomenico, F., Farese, S., Chiara, M. D., Balbo, C., Cappabianca, S., & Fasano, M. (2024) · Biomedicines · doi:10.3390/biomedicines12092080 · Cited by 14 · see citing works
Roichman, A., Reyes‐Castellanos, G., Chen, Z., Chen, Z., Mitchell, S. J., MacArthur, M. R., Sawant, A., Levett, L., Powers, J. R., Burgo, V., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-4378 · Cited by 14 · see citing works
Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease
Dietz, H., Weinmann, S. C., & Salama, A. K. S. (2021) · Cancer Management and Research · doi:10.2147/cmar.s283217 · Cited by 14 · see citing works
Comprehensive overview of COVID-19-related respiratory failure: focus on cellular interactions
Rarani, F. Z., Rarani, M. Z., Hamblin, M. R., Rashidi, B., Hashemian, S. M. R., & Mirzaei, H. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00363-3 · Cited by 14 · see citing works
Tavares, A. B. M. L. A., Neto, J. X., Fulco, U. L., & Albuquerque, E. L. (2021) · Physical Chemistry Chemical Physics · doi:10.1039/d1cp03064g · Cited by 13 · see citing works
Thier, B., Zhao, F., Stupia, S., Brüggemann, A., Koch, J., Schulze, N., Horn, S., Coch, C., Hartmann, G., Sucker, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003863 · Cited by 14 · see citing works
Barajas, A., Amengual-Rigo, P., Pons-Grífols, A., Ortiz, R., Carmona, O. G., Urrea, V., de la Iglesia, N., Blanco-Heredia, J., Souza, C. A., Varela, I., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04843-8 · Cited by 13 · see citing works
Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and TumorPreprint
Blum, S. M., Zlotoff, D. A., Smith, N. P., Kernin, I., Ramesh, S., Zubiri, L., Caplin, J., Samanta, N., Martin, S., Tirard, A. J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.15.557794 · Cited by 13 · see citing works
Clonal Spreading of Tumor-Infiltrating T Cells Underlies the Robust Antitumor Immune Responses
Aoki, H., Tsunoda, M., Ogiwara, H., Shimizu, H., Abe, H., Ogawa, T., Abe, T., Shichino, S., Matsushima, K., & Ueha, S. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0517 · Cited by 12 · see citing works
Barnwal, A., Tamang, R., Das, S., & Bhattacharyya, J. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02316-9 · Cited by 13 · see citing works
Synthesis of new class of indole acetic acid sulfonate derivatives as ectonucleotidases inhibitors
Jadoon, M. S. K., Pelletier, J., Sévigny, J., & Iqbal, J. (2023) · RSC Advances · doi:10.1039/d3ra04266a · Cited by 11 · see citing works
Mukund, K., Veraksa, D., Frankhouser, D. E., Yang, L., Tomšič, J., Pillai, R. K., Atti, S., Mesrizadeh, Z., Schmolze, D. D., Zabaleta, J., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116752 · Cited by 11 · see citing works
Harnessing the potential of gene editing technology for CAR-T cell therapy of solid tumors
Khodabandehloo, E., Rayati, M., Ahmadi, E., Naghdibadi, M., Moradi, V., & Ahmadbeigi, N. (2025) · Inflammation and Regeneration · doi:10.1186/s41232-025-00398-x · Cited by 12 · see citing works
Campbell, K. M., Thaker, M., Medina, E., Kalbasi, A. K., Singh, A. S., Ribas, A., & Nowicki, T. S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004190 · Cited by 10 · see citing works
Pacholczak‐Madej, R., Kosałka-Węgiel, J., Kuszmiersz, P., Mituś, J. W., Püsküllüoğlu, M., Grela-Wojewoda, A., Korkosz, M., & Bazan‐Socha, S. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20064926 · Cited by 10 · see citing works
Divergent Resistance Mechanisms to Immunotherapy Explain Responses in Different Skin Cancers
Dollinger, E., Bergman, D. R., Zhou, P., Atwood, S. X., & Nie, Q. H. (2020) · Cancers · doi:10.3390/cancers12102946 · Cited by 10 · see citing works
- Authors
- Frohne, C. C., Llano, E. M., Perkovic, A., Cohen, R. D., & Luke, J. J.
- Affiliations
- University of Chicago (US)
- Corresponding author
- Luke, Jason J.
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2019-01-06
- Volume
- 7
- Issue
- 1
- Pages
- 1-1
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC6322234
- OpenAlex
- W2917853396
- Cited by
- 171
- References
- 20
- Citations by year
- 2026: 2 · 2025: 28 · 2024: 25 · 2023: 24 · 2022: 22 · 2021: 42 · 2020: 22 · 2019: 5
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Department of Defense Career Development Award (W81XWH-17-1-0265)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- metastatic melanoma, Crohn's disease, immune checkpoint inhibitors, pembrolizumab, vedolizumab, anti-PD-1, autoimmune disease, immunosuppressive therapy, immune-related adverse events, pulmonary nodules, complete response
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Crohn Disease, Humans, Immunosuppression Therapy, Male, Melanoma, Middle Aged, Integrins, Treatment Outcome, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
